Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( NASDAQ:VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy - Vera Therapeutics ( NASDAQ:VERA )
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 ( p<0.0001 )
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with ...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase ...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( NASDAQ:VERA ) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase ...
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
BRISBANE, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy ( IgAN ) were presented as a featured late-breaking oral presentation during the opening plenary session of the ...
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September ...
Capricorn Fund Loads Up on Phreesia ( PHR ) With a 484,000 Share Purchase
Capricorn Fund Managers Ltd disclosed a new stake in Phreesia ( NYSE:PHR ) , purchasing 484,500 shares valued at $11.4 million as of September 30, 2025. The transaction, detailed in a Securities and Exchange Commission ( SEC ) filing dated October 17, 2025, marks the fund's initial reportable ...
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( NASDAQ:VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that data from the ...
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week ...
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market - Vera Therapeutics ( NASDAQ:VERA )
BofA Securities initiated coverage on Vera Therapeutics, Inc. ( NASDAQ:VERA ) , ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Climb Bio ( NASDAQ:CLYM ) , Celestica ( NYSE:CLS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. William Blair analyst Matt Phipps initiated coverage on Climb Bio Inc ( NASDAQ:CLYM ) with an ...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase ...
6 Stocks Poised For Potential Acquisition In The Next 12 Months, According To Goldman Sachs, Including A 200% YTD Gainer - ( AACT ) , Walt Disney ( NYSE:DIS )
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. The bank reported that the total dollar value of M&A deals has risen 29% year-over-year, with deal volumes in 2025 climbing 8%. The bank projects an additional 15% increase in new ...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 85,000 shares of ...
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A ...
Vera ( VERA ) Q2 Net Loss Widens 127%
Vera Therapeutics ( NASDAQ:VERA ) , a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its widening net loss to $76.5 million, or $1.20 per share ( GAAP ) , compared to analyst expectations ...
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics ( NASDAQ:ALLO ) , AvalonBay Communities ( NYSE:AVB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Brian Cheng downgraded the rating for Allogene Therapeutics, Inc.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif. , July 10, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., June 09, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted ...
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results - ABM Indus ( NYSE:ABM ) , Docusign ( NASDAQ:DOCU )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 1% on Friday. The Dow traded up 1.05% to 42,765.32 while the NASDAQ gained 1.31% to 19,551.81. The S&P 500 also rose, gaining, 1.10% to 6,004.74. In trading on Friday, utilities stocks fell by 0.2%.
Dow Jumps Over 500 Points; Nonfarm Payrolls Top Estimates - Davis Commodities ( NASDAQ:DTCK ) , EPWK Holdings ( NASDAQ:EPWK )
U.S. stocks traded higher this morning, with the Dow Jones jumping more than 500 points on Friday. Following the market opening Friday, the Dow traded up 1.29% to 42,867.21 while the NASDAQ gained 1.34% to 19,557.93. The S&P 500 also rose, gaining, 1.17% to 6,008.98.
Lululemon Cuts Earnings Forecast, Joins DocuSign, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Braze ( NASDAQ:BRZE ) , Docusign ( NASDAQ:DOCU )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of lululemon athletica inc. LULU fell sharply in today's pre-market trading after the company cut its FY25 GAAP EPS guidance below estimates.
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Applied Digital ( NASDAQ:APLD ) , Lyra Therapeutics ( NASDAQ:LYRA )
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday. The Dow traded down 0.49% to 42,064.07 while the NASDAQ rose 0.21% to 19,154.77. The S&P 500 also fell, dropping, 0.11% to 5,905.30. In trading on Monday, real estate stocks fell by 1.5%.
Vera Therapeutics Releases Trial Data, Stock Price Soars - Vera Therapeutics ( NASDAQ:VERA )
Atacicept led to a 42% reduction in UPCR versus placebo at week 36 ( p<0.0001 ) in adults with IgAN. Participants saw a 46% proteinuria drop from baseline with atacicept in the ORIGIN Phase 3 trial. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - Vera Therapeutics ( NASDAQ:VERA )
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria ( UPCR ) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 ( p<0.0001 )
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
BRISBANE, Calif., June 02, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy ( IgAN ) in adults.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., April 09, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch - Vera Therapeutics ( NASDAQ:VERA )
ORIGIN 3 fully enrolled with 431 participants to assess atacicept in IgAN over 104 weeks Primary data readout on proteinuria reduction expected this quarter from 36-week interim Feel unsure about the market's next move?
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
EXTON, PA, March 26, 2025 ( GLOBE NEWSWIRE ) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy ( IgAN ) .
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., March 11, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted ...
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
BRISBANE, Calif., Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business ...
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Expand Energy ( NASDAQ:EXE ) , Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top 3 Health Care Stocks That Could Blast Off This Quarter - Vera Therapeutics ( NASDAQ:VERA ) , RadNet ( NASDAQ:RDNT )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
What's Going On With Vera Therapeutics Stock? - Vera Therapeutics ( NASDAQ:VERA )
Vera Therapeutics shares are trading lower by 7.3% Monday afternoon. Vera Therapeutics Inc VERA shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109.
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Jan. 13, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Nov. 22, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of ...
Wall Street Analysts Think Vera Therapeutics ( VERA ) Could Surge 27.26%: Read This Before Placing a Bet
The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics to Participate at Upcoming Investor Conferences - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an ...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a ...
